Mayo Clinic Proceedings Home

Clinical Comparison of Borreliacidal-Antibody Test With Indirect Immunofluorescence and Enzyme-Linked Linked Immunosorbent Assays for Diagnosis of Lyme Disease


      To compare the clinical results with the borreliacidal-antibody test (BAT) and two standard screening serologic tests for Lyme disease (LD)—the indirect immunofluorescence assay (IFA) and the enzyme-linked immunosorbent assay (ELISA).


      The medical records of patients from an endemic LD area, who had been serologically tested during the summer of 1992, were retrospectively categorized by clinical diagnoses without results of serologic tests. Serologic testing, which included control serum samples from patients from a nonendemic LD area, was performed in a blinded fashion, and the results were compared with the clinical categories.

      Material and Methods

      Medical records of 307 patients who had been serologically tested for LD were reviewed. We found untreated, active LD in 43 patients (early-localized LD, 21; early-disseminated LD, 14; and late-disseminated LD, 8) and treated LD in 33. Non-LD cases were categorized into acute or chronic conditions of unknown or known cause.


      Overall, the BAT had a sensitivity of 11% in active LD and did not correlate with results of other conventional surface antibody assays. The IF A and ELISA were more sensitive (67 to 93%), but false-positive results frequently were noted (20 to 40%) in acute and chronic non-LD inflammatory conditions. The specificity of the BAT, IFA, and ELISA in the control group was 96%, 93%, and 97%, respectively.


      Until the sensitivity, as measured by prospective clinical studies, is improved without loss of specificity, the BAT should not be used clinically for the diagnosis of LD. Suspected cases of LD with atypical clinical manifestations should have positive ELISA and IFA results confirmed with a standardized immunoblot assay.
      BAT (borreliacidal-antibody test), BSK (Barbour-Stoenner Kelly), ELISA (enzyme-linked immunosorbent assay), EM (erythema migrans), IFA (indirect immunofluorescence assay), LD (Lyme disease), PBS (phosphate-buffered saline)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Magnarelli LA
        Serologie diagnosis of Lyme disease.
        Ann N Y AcadSci. 1988; 539: 154-161
        • Russell H
        • Sampson JS
        • Schmid GP
        • Wilkinson HW
        • Plikaytis B
        Enzyme-linked immunosorbent assay and indirect immunofluores-cence assay for Lyme disease.
        J Infect Dis. 1984; 149: 465-470
        • Feder Jr, HM
        • Gerber MA
        • Luger SW
        • Ryan RW
        Persistence of serum antibodies to Borrelia burgdorferi in patients treated for Lyme disease.
        Clin Infect Dis. 1992; 15: 788-793
        • Hammers-Berggren S
        • Lebech AM
        • Karlsson M
        • Svenungsson B
        • Hansen K
        • Stiernstedt G
        Serological follow-up after treatment of patients with erythema migrans and neuroborreliosis.
        J Clin Microbiol. 1994; 32: 1519-1525
        • Kaell AT
        • Redecha PR
        • Elkon KB
        • Golightly MG
        • Schulman PE
        • Dattwyler RJ
        • et al.
        Occurrence of antibodies to Borrelia burgdorferi in patients with nonspirochetal subacute bacterial endocarditis.
        Ann Intern Med. 1993; 119: 1079-1083
        • Callister SM
        • Schell RF
        • Lovrich SD
        Lyme disease assay which detects killed Borrelia burgdorferi.
        J Clin Microbiol. 1991; 29: 1773-1776
        • Sadziene A
        • Thompson PA
        • Barbour AG
        In vitro inhibition of Borrelia burgdorferi growth by antibodies.
        J Infect Dis. 1993; 167: 165-172
        • Callister SM
        • Schell RF
        • Case KL
        • Lovrich SD
        • Day SP
        Characterization of the borreliacidal antibody response to Borrelia burgdorferi in humans: a sérodiagnostic test.
        J Infect Dis. 1993; 167: 158-164
        • Callister SM
        • Schell RF
        • Lim LCL
        • Jobe DA
        • Case KL
        • Bryant GL
        • et al.
        Detection of borreliacidal antibodies by flow cytometry: an accurate, highly specific sérodiagnostic test for Lyme disease.
        Arch Intern Med. 1994; 154: 1625-1632
        • Agger WA
        Isolating Borrelia burgdorferi from erythema migrans [letter].
        Ann Intern Med. 1993; 119: 953-954
        • Agger W
        • Case KL
        • Bryant GL
        • Callister SM
        Lyme disease: clinical features, classification, and epidemiology in the upper midwest.
        Medicine. 1991; 70: 83-90
        • Nocton JJ
        • Dressier F
        • Rutledge BJ
        • Rys PN
        • Persing DH
        • Steere AC
        Detection of Borrelia burgdorferi DNA by polymerase chain reaction in synovial fluid from patients with Lyme arthritis.
        N Engl J Med. 1994; 330: 229-234
        • Mitchell PD
        • Reed KD
        • Aspeslet TL
        • Vandermause MF
        • Melski JW
        Comparison of four immunoserologic assays for detection of antibodies to Borrelia burgdorferi in patients with culture-positive erythema migrans.
        J Clin Microbiol. 1994; 32: 1958-1962
        • Corpuz M
        • Hilton E
        • Lardis MP
        • Singer C
        • Zolan J
        Problems in the use of sérologie tests for the diagnosis of Lyme disease.
        Arch Intern Med. 1991; 151: 1837-1840
        • Fister RD
        • Weymouth LA
        • McLaughlin JC
        • Ryan RW
        • Tilton RC
        Comparative evaluation of three products for the detection of Borrelia burgdorferi antibody in human serum.
        J Clin Microbiol. 1989; 27: 2834-2837
        • Hedberg CW
        • Osterholm MT
        • MacDonald KL
        • White KE
        An interlaboratory study of antibody to Borrelia burgdorferi.
        J Infect Dis. 1987; 155: 1325-1327
        • Luger SW
        • Krauss E
        Serologie tests for Lyme disease: interlaboratory variability.
        Arch Intern Med. 1990; 150: 761-763
        • Schwartz BS
        • Goldstein MD
        • Ribeiro JMC
        • Schulze TL
        • Shahied SI
        Antibody testing in Lyme disease: a comparison of results in four laboratories.
        JAMA. 1989; 262: 3431-3434
        • Dressier F
        • Whalen JA
        • Reinhardt BN
        • Steere AC
        Western blotting in the serodiagnosis of Lyme disease.
        J Infect Dis. 1993; 167: 392-400
        • Engstrom SM
        • Shoop E
        • Johnson RC
        Immunoblot interpretation criteria for serodiagnosis of early Lyme disease.
        J Clin Microbiol. 1995; 33: 419-427
        • Centers for Disease Control and Prevention
        Lyme disease surveillance summary. 1995; 6: l-4
        • Zoller L
        • Burkard S
        • Schafer H
        Validity of Western immunoblot band patterns in the serodiagnosis of Lyme borreliosis.
        J Clin Microbiol. 1991; 29: 174-182
        • Gabritschewsky G
        Les bases de la sérothérapie de la fièvre récurrente.
        Ann Inst Pasteur. 1896; 10: 630-659
        • Callister SM
        • Jobe DA
        • Schell RF
        • Pavia CS
        • Lovrich SD
        Sensitivity and specificity of the borreliacidal-antibody test during early Lyme disease: a 'gold standard'?.
        Clin Diagn Lab Immunol. 1996; 3: 399-402
        • Lachs MS
        • Nachamkin I
        • Edelstein PH
        • Goldman J
        • Feinstein AR
        • Schwartz JS
        Spectrum bias in the evaluation of diagnostic tests: lessons from the rapid dipstick test for urinary tract infection.
        Ann InternMed. 1992; 117: 135-140
        • Centers for Disease Control and Prevention
        Recommendations for test performance and interpretation from the Second National Conference on Serologie Diagnosis of Lyme Disease.
        MMWR Morb Mortal Wkly Rep. 1995; 44: 590-591
        • Hilton E
        • Devoti J
        • Sood S
        Recommendation to include OspA and OspB in the new immunoblotting criteria for serodiagnosis of Lyme disease.
        J Clin Microbiol. 1996; 34: 1353-1354